Mesenchymal Stem Cell and Islet Co-transplantation

Medical University of South Carolina3 enrolled

Overview

The purpose of this study is to show safety and tolerability to our mesenchymal stromal cells (MSCs) product which will be autologous in nature, expanded using a non-xenogeneic, human component expansion media (pooled human platelet lysate) and delivered fresh. Subsequently, the investigators intend to test whether infusion of MSCs immediately after islet autograft can reduce onset of diabetes and improve glycemic control after total pancreatectomy and islet autotransplantation.

This is a Phase I study evaluating safety and tolerability of autologous BM-MSCs in chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation (TP-IAT). CCT-BMMSC will be infused at one of the following doses: (Tier 1), 20x10\^6 cell per patient, (Tier 2), 50x10\^6 cell per patient, and (Tier 3), 100x10\^6 cell per patient. Primary objective: To describe and compare the safety and tolerability of infusion of fresh autologous bone marrow-derived Mesenchymal stromal cells after islet transplantation in chronic pancreatitis patients who undergo TP-IAT. The investigators plan to enroll 24 patients for the whole study. The duration of this study is 12 months. The investigators anticipate that this study will be completed within 2 years of commencement. Secondary objective: Efficacy of infusion of fresh autologous bone marrow-derived Mesenchymal stromal cells together after islet transplantation in chronic pancreatitis patients who undergo TP-IAT as assessed through onset of diabetes, glycemic control, pain relief and quality of life index. Safety variables: Adverse events (AEs), Laboratory parameters (hematology, biochemistry, urinalysis), Vital signs

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Chronic Pancreatitis Diabetes

Interventions

autologous mesenchymal stromal cellBIOLOGICAL

Islet transplantation patients will receive autologous MSCs following islets infusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 69 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic pancreatitis patients who undergo TP-IAT. * \>18 years of age. * Patients with BMI from 18.5 to 30. * Renal function: \>90mls/min/1.73m squared * Normal INR/PT/PTT values for MUSC clinical laboratory standards * Diabetes free before surgery (fasting blood glucose\<125mg/dl). * No prior pancreatic surgery with the exception of transduodenal sphincteroplasty or Whipple/Beger procedure. * Patients with normal liver function as measured by serum levels of aminotransferase including alanine aminotransferase (ALT), and aspartate aminotransferase (AST), and total bilirubin levels. Exclusion Criteria: * Patients whose Hemoglobin, Hematocrit, and Platelet count are above or below normal values for MUSC clinical laboratory standards. * Patients who has hematological malignancy. * Patients who are under immunosuppression. * Patients with marked calcification disease on CT scan. * Patients with severe fibrosis and atrophy on pancreas MRI.

Locations (1)

GI Surgery, Medical University of South Carolina

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

C-peptide level after mixed meal tolerance test

Time frame: 12 months

Secondary Outcomes

Liver function, kidney function

Time frame: 12 months after transplant

The absence of severe hypoglycemic episodes

Time frame: 12 months after transplant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.